PL398781A1 - Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy - Google Patents

Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy

Info

Publication number
PL398781A1
PL398781A1 PL398781A PL39878110A PL398781A1 PL 398781 A1 PL398781 A1 PL 398781A1 PL 398781 A PL398781 A PL 398781A PL 39878110 A PL39878110 A PL 39878110A PL 398781 A1 PL398781 A1 PL 398781A1
Authority
PL
Poland
Prior art keywords
kits
predicting
developing
risk
loss
Prior art date
Application number
PL398781A
Other languages
English (en)
Inventor
Theresa Rosario-Jansen
David Erick Wright
Original Assignee
Savient Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals, Inc. filed Critical Savient Pharmaceuticals, Inc.
Publication of PL398781A1 publication Critical patent/PL398781A1/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/906—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7)
    • G01N2333/90688—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on other nitrogen compounds as donors (1.7)
    • G01N2333/90694—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3), e.g. uricase (1.7.3.3)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/107—Crystal induced conditions; Gout
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
PL398781A 2009-06-25 2010-06-25 Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy PL398781A1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26966909P 2009-06-25 2009-06-25
US24869809P 2009-10-05 2009-10-05
US29871810P 2010-01-27 2010-01-27

Publications (1)

Publication Number Publication Date
PL398781A1 true PL398781A1 (pl) 2012-11-19

Family

ID=43386920

Family Applications (1)

Application Number Title Priority Date Filing Date
PL398781A PL398781A1 (pl) 2009-06-25 2010-06-25 Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy

Country Status (24)

Country Link
US (11) US9377454B2 (pl)
EP (3) EP2446260B1 (pl)
JP (2) JP2012531596A (pl)
KR (1) KR101861547B1 (pl)
CN (1) CN102803954A (pl)
AU (1) AU2010265964B2 (pl)
BR (1) BRPI1010069A2 (pl)
CA (1) CA2766309A1 (pl)
CZ (1) CZ2011827A3 (pl)
DK (1) DK3482768T3 (pl)
ES (1) ES3066542T3 (pl)
FI (1) FI3482768T3 (pl)
HR (1) HRP20260434T1 (pl)
HU (1) HUP1200205A3 (pl)
IL (1) IL216956A (pl)
LT (1) LT3482768T (pl)
MX (1) MX347903B (pl)
NZ (1) NZ597089A (pl)
PL (1) PL398781A1 (pl)
PT (1) PT3482768T (pl)
RU (1) RU2535038C2 (pl)
SG (2) SG176897A1 (pl)
SM (1) SMT202600157T1 (pl)
WO (1) WO2010151823A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
DK3321359T3 (da) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc Variante former af uratoxidase og anvendelse deraf
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
KR20140041505A (ko) 2011-04-29 2014-04-04 셀렉타 바이오사이언시즈, 인크. 조절 b 세포 유도를 위한 관용원성 합성 나노운반체
BR112015027291A8 (pt) 2013-05-03 2019-12-24 Selecta Biosciences Inc uso de um imunossupressor que têm uma vida eficaz farmacodinâmica especificada e composição compreendendo o referido imunossupressor
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016037164A1 (en) 2014-09-07 2016-03-10 Selecta Biosciences, Inc. Methods and compositions for attenuating gene expression modulating anti-viral transfer vector immune responses
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
AU2016265677B2 (en) 2015-05-15 2021-12-09 Medimmune, Llc Improved uricase sequences and methods of treatment
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
US20200237881A1 (en) * 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
CA3069197A1 (en) 2017-07-07 2019-01-10 Allena Pharmaceuticals, Inc. Recombinant uricase enzyme
WO2020160324A1 (en) * 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
EP3980784A1 (en) * 2019-06-04 2022-04-13 Selecta Biosciences, Inc. Formulations and doses of pegylated uricase
EP4021482A4 (en) * 2019-08-30 2023-04-19 Horizon Therapeutics Ireland Dac PEGLOTICASE FOR THE TREATMENT OF GOUT IN KIDNEY TRANSPLANT RECIPIENT
EP4153235A4 (en) 2020-05-22 2025-04-30 AAB Therapeutics, LLC Compounds and methods for suppressing an immune response to substances containing polyethylene glycol
AU2021324665A1 (en) 2020-08-10 2023-04-13 Horizon Therapeutics Usa, Inc. Methods of treating gout
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (167)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (pl)
DE279489C (pl)
US1016095A (en) 1910-09-08 1912-01-30 Gen Electric Splicing-sleeve.
US1141973A (en) 1911-05-22 1915-06-08 Jesse W Nichols Can-cap with vent-shield.
DE837379C (de) 1950-04-20 1955-08-16 Nordwind G M B H Windkraftanlage, insbesondere zum Antrieb einer Kolbenpumpe
US3451996A (en) 1968-02-12 1969-06-24 Thompson Farms Co Method for the preparation of heparin
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US3613231A (en) 1969-07-25 1971-10-19 Paul F Pugh Method for manufacturing high voltage cable systems
US3931399A (en) 1970-12-22 1976-01-06 Behringwerke Aktiengesellschaft Process for isolating a fibrin-stabilizing factor
AU461334B2 (en) 1971-04-05 1975-05-22 Rca Ogrforaxicn Radiofrequency transistor structure and method for making
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4027676A (en) 1975-01-07 1977-06-07 Ethicon, Inc. Coated sutures
US4169764A (en) 1975-08-13 1979-10-02 Ajinomoto Co., Inc. Process for production of urokinase
US4141973A (en) 1975-10-17 1979-02-27 Biotrics, Inc. Ultrapure hyaluronic acid and the use thereof
US4064010A (en) 1976-07-21 1977-12-20 Eastman Kodak Company Purification of uricase
US4301153A (en) 1977-03-21 1981-11-17 Riker Laboratories, Inc. Heparin preparation
US4425431A (en) 1978-04-20 1984-01-10 Toyo Soda Manufacturing Co., Ltd. Production of an allose-containing polysaccharide
US4312979A (en) 1978-04-20 1982-01-26 Toyo Soda Manufacturing Co., Ltd. Polysaccharides containing allose
JPS6031472B2 (ja) 1978-12-14 1985-07-22 協和醗酵工業株式会社 酸性ウリカ−ゼ
US4251431A (en) 1979-01-16 1981-02-17 Shell Oil Company Lubricating greases
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
DE2916711A1 (de) 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung
DE2943016C2 (de) 1979-10-24 1984-09-06 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Verfahren zur Reinigung von Interferon
JPS5651995A (en) 1979-10-05 1981-05-09 Green Cross Corp:The Preparation of interferon
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
DE3005897A1 (de) 1980-02-16 1981-09-03 Hoechst Ag, 6000 Frankfurt Genprodukt eines hoeheren organismus aus einem dieses gen enhtaltenden mikroorganismus
FR2475900A1 (fr) 1980-02-20 1981-08-21 Fabre Sa Pierre Complexe vaccinal contenant un antigene specifique et vaccin le contenant
CH651308A5 (de) 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
JPS5740503A (en) 1980-08-22 1982-03-06 Seikagaku Kogyo Co Ltd Separation of saccharides
US4315852A (en) 1980-11-26 1982-02-16 Schering Corporation Extraction of interferon from bacteria
FR2497006A1 (fr) 1980-12-24 1982-06-25 Ind Electro Ste Gle Contacts electriques pour cables coaxiaux et cables bifilaires
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4450103A (en) 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4485176A (en) 1982-06-28 1984-11-27 E. I. Du Pont De Nemours & Company Turbidimetric method for measuring protein in urine and cerebrospinal fluid
EP0109688A3 (en) 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
USD279486S (en) 1983-04-25 1985-07-02 International Jensen Incorporated Controller for a video game or the like
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPH0671425B2 (ja) 1985-06-05 1994-09-14 サッポロビール株式会社 ウリカ−ゼおよびその製造法
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) 1985-06-26 1991-02-07 Cetus Corp Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4847079A (en) 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
AU597924B2 (en) 1985-12-11 1990-06-14 Natinco Nv Solubilization of protein aggregates
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
JPS6255079A (ja) 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
JPS63203548A (ja) 1987-02-12 1988-08-23 四国化工機株式会社 飲料用密封容器の製造装置
AU612133B2 (en) 1987-02-20 1991-07-04 Natinco Nv Production of proteins in active forms
CA1305285C (en) 1987-04-21 1992-07-14 Malcolm Roy Brandon Production of proteins in active forms
AU609824B2 (en) 1987-06-15 1991-05-09 Southern Cross Biotech Pty Ltd. Production of proteins in active forms
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
CA1286591C (en) 1987-12-18 1991-07-23 Douglas B. Taylor Apparatus for opening and closing roll-up door
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JPH01216939A (ja) 1988-02-24 1989-08-30 Hoechst Japan Kk 末熟児頭蓋内出血阻止剤
US4945086A (en) 1988-05-03 1990-07-31 The Board Of Trustees Of The Leland Stanford Junior University Smooth muscle cell growth inhibitor
US5955336A (en) 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
JP3148208B2 (ja) 1988-10-31 2001-03-19 富士ゼロックス株式会社 マルチ出力トレイ付プリントサーバおよびプリントシステム
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5010183A (en) 1989-07-07 1991-04-23 Macfarlane Donald E Process for purifying DNA and RNA using cationic detergents
NZ234453A (en) 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5382518A (en) 1989-07-13 1995-01-17 Sanofi Urate oxidase activity protein, recombinant gene coding therefor, expression vector, micro-organisms and transformed cells
JPH0354581A (ja) 1989-07-24 1991-03-08 Nec Corp 電子写真系プリンタの現像カートリッジ
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
ATE167230T1 (de) 1989-08-23 1998-06-15 Hadassah Med Org Wundheilmittel enthaltend heparanase
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
GEP20033082B (en) 1991-03-15 2003-10-27 Amgen Inc Pegylation of Polypeptides
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
YU66892A (sh) 1991-08-20 1995-10-24 Hoechst Ag. Fosfoinositolglikan - peptid sa delovanjem kao insulin
JP3148298B2 (ja) 1991-09-02 2001-03-19 帝人株式会社 軽量複合成形物の製造法
US5298643A (en) 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
JP3875730B2 (ja) 1993-02-22 2007-01-31 サノフィ・アベンティス株式会社 自己免疫疾患の予防治療剤
US6385312B1 (en) 1993-02-22 2002-05-07 Murex Securities, Ltd. Automatic routing and information system for telephonic services
US5298410A (en) 1993-02-25 1994-03-29 Sterling Winthrop Inc. Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life
JPH06255079A (ja) 1993-03-08 1994-09-13 Akira Totsuka 被服地のスクリーン印刷装置及び被服地のスクリーン印刷方法
US5863534A (en) 1993-04-09 1999-01-26 Bio-Technology General Corp. Polypeptide having factor Xa inhibitory method of reducing blood coagulation with a novel polypeptide having factor Xa inhibitory activity
ES2155472T3 (es) 1993-04-09 2001-05-16 Bio Technology General Corp Nuevo polipeptido con actividad inhibidora del factor xa.
WO1994023740A1 (en) 1993-04-22 1994-10-27 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
WO1995000162A1 (en) 1993-06-21 1995-01-05 Enzon, Inc. Site specific synthesis of conjugated peptides
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
EP0730660A4 (en) 1993-10-29 1998-02-25 Incyte Pharma Inc CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS
DE69430251T2 (de) 1993-11-10 2002-11-07 Enzon, Inc. Verbesserte interferon-polymerkonjugate
US5656279A (en) 1994-02-23 1997-08-12 Bio Med Sciences, Inc. Semi-interpenetrating polymer network scar treatment sheeting, process of manufacture and useful articles thereof
US5795776A (en) 1994-03-22 1998-08-18 Bio-Technology General Corp. Expression plasmids regulated by an OSMB promoter
FI96317C (fi) 1994-05-31 1996-06-10 Exavena Oy Menetelmä hienojakoisten ja muunnettujen tärkkelyksien valmistamiseksi
DE4423131A1 (de) 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5633227A (en) 1994-09-12 1997-05-27 Miles, Inc. Secretory leukocyte protease inhibitor as an inhibitor of tryptase
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU697440B2 (en) 1994-12-07 1998-10-08 Novozymes A/S Polypeptide with reduced allergenicity
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
IL116696A (en) 1995-01-25 1999-08-17 Bio Technology General Corp Production of enzymatically active recombinant carboxypeptidase b
TW426523B (en) 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
CN1168495C (zh) 1997-01-15 2004-09-29 凤凰药理学公司 被修饰的肿瘤坏死因子
US5816397A (en) 1997-01-21 1998-10-06 Ogio International, Inc. Golf club carrying apparatus
JP2001511162A (ja) 1997-02-06 2001-08-07 ノボ ノルディスク アクティーゼルスカブ 付加され、そして／又は除去された付着基を有するポリペプチド−ポリマー結合体
KR100369838B1 (ko) 1997-02-26 2003-09-29 주식회사 엘지생명과학 한국형c형간염바이러스의비구조단백질3에서유래한단백질분해효소단백질및그의제조방법
US6821763B2 (en) 1997-07-04 2004-11-23 Ajinomoto Co., Inc. Process for producing microbial transglutaminase
JPH1175876A (ja) 1997-07-04 1999-03-23 Ajinomoto Co Inc 新規な微生物トランスグルタミナーゼの製造法
EP1084136B1 (en) 1998-06-01 2004-08-25 Genentech, Inc. Separation of antibody monomers from its multimers by use of ion-exchange chromatography
US20060188971A1 (en) 1998-08-06 2006-08-24 Duke University Urate oxidase
EP2158923B1 (en) 1998-08-06 2013-02-27 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
EP1100542B1 (en) 1998-08-06 2005-06-22 Mountain View Pharmaceuticals, Inc. Peg-urate oxidase conjugates and use thereof
CA2337967C (en) 1998-08-06 2011-11-01 Duke University Recombinant uricase protein
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6429860B1 (en) 1999-06-15 2002-08-06 Visicomp, Inc. Method and system for run-time visualization of the function and operation of a computer program
CA2398823A1 (en) 2000-02-14 2001-08-23 First Opinion Corporation Automated diagnostic system and method
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
US20050084478A1 (en) 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
AU2002306651B2 (en) 2001-03-02 2007-12-13 Medimmune, Llc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav Beta3 antagonists
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
AU2002365360A1 (en) 2001-11-28 2003-06-10 Biopolymed Inc. Biologically active non-antigenic copolymer and conjugates thereof and methods for producing the same
AU2004230670B2 (en) 2003-01-09 2010-11-25 Genentech, Inc. Purification of polypeptides
JP4273998B2 (ja) 2004-02-26 2009-06-03 学校法人東海大学 プロテオーム解析用試料の調製方法
WO2005110386A2 (en) 2004-04-13 2005-11-24 Wisconsin Alumni Research Foundation Method of decreasing inflammation in kidney transplantation using angiotensin receptor blockers
CN103088038B (zh) 2004-07-12 2015-06-24 美国天甲生物医药有限公司 黄病毒疫苗
GB0420888D0 (en) 2004-09-20 2004-10-20 Photopharmica Ltd Compounds and uses
CN102807973A (zh) 2005-04-11 2012-12-05 萨文特医药公司 尿酸氧化酶的变体形式及其用途
US20080159976A1 (en) 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
DK3321359T3 (da) 2005-04-11 2021-03-08 Horizon Pharma Rheumatology Llc Variante former af uratoxidase og anvendelse deraf
WO2008051178A2 (en) 2006-04-12 2008-05-02 Savient Pharmaceuticals, Inc. Purification of proteins with cationic surfactant
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1988956A2 (en) 2006-02-22 2008-11-12 Novartis Pharma AG System for delivering nebulized cyclosporine and methods of treatment
NL1031926C2 (nl) 2006-05-31 2007-12-03 X Flow Bv Inrichting met een bioreactor en membraanfiltratiemodule voor het behandelen van een inkomend fluïdum.
CN100558403C (zh) 2006-10-23 2009-11-11 中国科学院理化技术研究所 双壳层药物缓控释载体材料及其制备方法和用途
WO2008063663A2 (en) 2006-11-21 2008-05-29 University Of Southern California Poly (ethylene glycol) anti-body detection assays and kits for performing thereof
CN101168052A (zh) 2007-10-26 2008-04-30 西安交通大学 一种防治高尿酸血症及痛风的肠溶制剂
FR2924271B1 (fr) 2007-11-27 2010-09-03 Picogiga Internat Dispositif electronique a champ electrique controle
WO2010031051A1 (en) 2008-09-15 2010-03-18 Elan Pharmaceuticals, Inc. Methods of treatment of hyperuricemia and associated disease states
WO2010071865A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
US20100160351A1 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Pharmaceutical compositions and methods for treating hyperuricemia and related disorders
RU2535038C2 (ru) 2009-06-25 2014-12-10 Криэлта Фармасьютикалз ЭлЭлСи Способы и наборы для прогнозирования риска инфузионных реакций и опосредованной антителами потери ответа при терапии пэгилированной уриказой с помощью мониторинга содержания мочевой кислоты в сыворотке крови
KR20120135183A (ko) 2009-06-25 2012-12-12 코어랩 파트너스, 인코포레이티드 결절성 통풍 치료에서의 요산염 저하 요법 동안의 통풍결절 반응을 평가하는 방법
WO2011032175A1 (en) 2009-09-14 2011-03-17 Nuon Therapeutics, Inc. Combination formulations of tranilast and allopurinol and methods related thereto
JP5451464B2 (ja) 2010-03-09 2014-03-26 キヤノン株式会社 帯電装置
CA2794798C (en) 2010-03-30 2017-05-30 Ardea Biosciences, Inc. Treatment of gout
CA2859693C (en) 2011-11-04 2018-05-22 Cymabay Therapeutics, Inc. Methods for treating gout flares
JP5888130B2 (ja) 2012-06-06 2016-03-16 富士通株式会社 通信端末装置および通信制御方法
JP5746101B2 (ja) 2012-06-18 2015-07-08 コスメディ製薬株式会社 マイクロニードルの迅速溶解法
GB2512876A (en) 2013-04-09 2014-10-15 Image Analysis Ltd Methods and apparatus for quantifying inflammation
WO2015150995A1 (en) 2014-04-04 2015-10-08 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
IL318183A (en) 2016-03-11 2025-03-01 Selecta Biosciences Inc Formulations and doses of pegylated uricase
US20180008665A1 (en) 2016-07-05 2018-01-11 CanTrust LifeScience Corp. Methods of treating and preventing gout and lead nephropathy
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
US20200237881A1 (en) 2019-01-30 2020-07-30 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
KR102753928B1 (ko) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. 항염증제, 및 면역억제제를 포함하는 합성 나노담체를 사용한 조합 치료와 관련된 방법 및 조성물
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
WO2020160324A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
EP4021482A4 (en) 2019-08-30 2023-04-19 Horizon Therapeutics Ireland Dac PEGLOTICASE FOR THE TREATMENT OF GOUT IN KIDNEY TRANSPLANT RECIPIENT
AU2021324665A1 (en) 2020-08-10 2023-04-13 Horizon Therapeutics Usa, Inc. Methods of treating gout

Also Published As

Publication number Publication date
US10823727B2 (en) 2020-11-03
US20240255496A1 (en) 2024-08-01
DK3482768T3 (da) 2026-04-07
US11598767B2 (en) 2023-03-07
JP2012531596A (ja) 2012-12-10
EP2446260A1 (en) 2012-05-02
MX2011013489A (es) 2012-05-29
US20190317083A1 (en) 2019-10-17
CZ2011827A3 (cs) 2012-09-26
RU2012102399A (ru) 2013-07-27
MX347903B (es) 2017-05-18
BRPI1010069A2 (pt) 2016-03-15
US12188927B2 (en) 2025-01-07
KR101861547B1 (ko) 2018-07-02
HRP20260434T1 (hr) 2026-05-08
US20210181187A1 (en) 2021-06-17
US12560596B2 (en) 2026-02-24
AU2010265964B2 (en) 2014-09-18
EP2446260A4 (en) 2013-11-20
HUP1200205A3 (en) 2012-09-28
US20230251247A1 (en) 2023-08-10
US20260118349A1 (en) 2026-04-30
CN102803954A (zh) 2012-11-28
US20180188242A1 (en) 2018-07-05
NZ597089A (en) 2014-05-30
EP3482768B1 (en) 2026-01-28
US11982670B2 (en) 2024-05-14
WO2010151823A1 (en) 2010-12-29
US20250231181A1 (en) 2025-07-17
US11639927B2 (en) 2023-05-02
SG10201408480RA (en) 2015-02-27
CA2766309A1 (en) 2010-12-29
US10139399B2 (en) 2018-11-27
US20160377604A1 (en) 2016-12-29
US20260023073A1 (en) 2026-01-22
AU2010265964A1 (en) 2012-02-02
SMT202600157T1 (it) 2026-05-12
EP2446260B1 (en) 2018-12-26
LT3482768T (lt) 2026-04-27
EP4635567A2 (en) 2025-10-22
US20230028134A1 (en) 2023-01-26
US20120301454A1 (en) 2012-11-29
SG176897A1 (en) 2012-01-30
ES3066542T3 (en) 2026-05-13
RU2535038C2 (ru) 2014-12-10
JP2015111137A (ja) 2015-06-18
IL216956A0 (en) 2012-02-29
US9377454B2 (en) 2016-06-28
EP4635567A3 (en) 2025-12-03
IL216956A (en) 2016-10-31
HUP1200205A2 (en) 2012-06-28
KR20120046125A (ko) 2012-05-09
PT3482768T (pt) 2026-04-02
FI3482768T3 (fi) 2026-03-27
EP3482768A1 (en) 2019-05-15

Similar Documents

Publication Publication Date Title
PT3482768T (pt) Métodos e kits para prevenir o risco de reação à infusão e a perda de resposta mediada por anticorpos através da monitorização do ácido úrico sérico durante a terapia com uricase peguilada
ZA201102252B (en) Methods and kits for nucleic acid sequencing
LU91864B1 (en) Method and kit for the isolation of genomic DNA, RNA, proteins and metabolites from a single biological sample
HUE054639T2 (hu) Nukleinsav-szekvencia kiegyensúlyozatlanságának meghatározása
DK2885641T3 (da) Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
EP2661494A4 (en) PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS AND METHODS FOR TREATING COLOR BLINDNESS AND OTHER PROBLEMS
IN2014CN04326A (pl)
WO2012076553A3 (en) Biomarkers and parameters for hypertensive disorders of pregnancy
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
HRP20150449T1 (xx) Metode lijeäśenja multiplog mijeloma primjenom kombiniranih terapija temeljenih na anti-cs1 antitijelima
EP2254897A4 (en) METHOD, REAGENTS AND KITS FOR DETECTING NUCLEIC ACID MOLECULES
WO2011149947A3 (en) Methods of determining amyloid beta turnover in blood
MX2012014284A (es) Metodos y kits para diagnosticar afecciones relacionadas con hipoxia.
EP2504348A4 (en) METHODS, REAGENTS AND KITS FOR DETECTING NUCLEIC ACID MOLECULES
WO2011047058A3 (en) Assay for the prediction of therapeutic effectiveness of mesenchymal stromal cells, and methods of using same
EE201000069A (et) Meetod ja elektrolser desinfitseeriva vahendi saamiseks
WO2011067711A3 (en) Novel heparanase splice variant
EP2297325A4 (en) METHODS OF STRATIFICATION, PROGNOSIS AND DIAGNOSIS OF SCHIZOPHRENIA, MUTANT NUCLEIC ACID MOLECULES AND POLYPEPTIDES
HK1206791A1 (en) Means and methods for response prediction of hepatitis b treatment
WO2012080721A3 (en) Plasma cell disorders
WO2009151337A3 (en) Novel retinoid inducible factor and uses thereof
NO20071496L (no) Elektrolytt og fremgangsmate for elektrokjemisk raffinering av silisium
EP2739733A4 (en) NUCLEIC ACID COMPOUNDS, PROCESSES AND KITS FOR FAST PAIRING OF AFFINITY MATERIALS
WO2012128799A3 (en) Treating schizophrenia
WO2011041725A3 (en) Schizophrenia treatment response biomarkers